All In Biotech

Drug Trial Radar · NCT05535764

AlloHCT With PegINFa for Myelofibrosis

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Aug 2, 2023

Primary completion

Jan 2027

Study completion Mar 2028

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Huntsman Cancer Institute
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.

Conditions

  • Myelofibrosis

Interventions

  • Pegylated interferon alpha2aDrug

    PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Start of treatment to 86 days after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huntsman Cancer Institute at the University of Utah

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.